Advertisment

Zanidatamab Shows Promise in Treating Heavily Pretreated HR+/HER2+ Metastatic Breast Cancer

author-image
Ethan Sulliva
New Update
NULL

Zanidatamab Shows Promise in Treating Heavily Pretreated HR+/HER2+ Metastatic Breast Cancer

Advertisment

A preliminary clinical trial has shown that a combination therapy including zanidatamab, a bispecific antibody targeting HER2, exhibits durable activity in patients with previously treated metastatic hormone receptor-positive (HR+)/HER2+ breast cancer. This promising development could pave the way for more effective treatments for patients with this particular type of breast cancer.

Advertisment

Study Overview and Results

The clinical trial, which was part of an international and multicenter study, evaluated the combination therapy of zanidatamab and standard-of-care therapies in patients with HR+/HER2+ breast cancer. The study population comprised 51 patients, most of whom had grade 3/4 treatment-related adverse events. Despite this, two-thirds of the patients remained progression-free at 6 months, and the median progression-free survival was 12 months. The therapy showed promising outcomes, durable responses, and a manageable safety profile in heavily pretreated patients.

Notably, the objective response rate was 35% overall, including 48% in the ccHER2+ subset. This means that nearly half of the patients with centrally confirmed HER2 status had objective responses, including three complete responses. Furthermore, the median duration of response was 15 months overall, and almost 80% of the patients experienced some degree of tumor shrinkage.

Advertisment

The Role of Zanidatamab

Zanidatamab, a HER2 targeted bispecific antibody, plays a crucial role in this combination therapy. In combination with palbociclib (a CDK4/6 inhibitor) and fulvestrant (a hormone therapy), it has shown meaningful progression-free survival outcomes with a manageable safety profile. This novel chemotherapy-free regimen is a promising development in the treatment of HR+/HER2+ metastatic breast cancer, a condition that can be difficult to treat.

Adverse Events and Safety Profile

Advertisment

While the combination therapy demonstrated promising results, it is important to note that two-thirds of the patients experienced grade 3/4 treatment-related adverse events. These included diarrhea, neutropenia, nausea, stomatitis, anemia, vomiting, and asthenia. Despite these side effects, the patients' responses to the therapy were largely positive, with many experiencing significant decreases in tumor size.

Further Development and Future Implications

The encouraging results of this trial support further development of this novel chemotherapy-free regimen. The combination of zanidatamab with palbociclib and fulvestrant could potentially provide a powerful new treatment option for patients with HR+/HER2+ metastatic breast cancer, particularly those who are heavily pretreated. Moreover, the significant progression-free survival and notable response rates seen in this trial suggest that this therapy could potentially improve the quality of life and outcomes for these patients.

In conclusion, the advent of zanidatamab and its promising results in combination therapy represent a significant step forward in the quest for more effective treatments for HR+/HER2+ metastatic breast cancer. As further research and clinical trials are conducted, it is hoped that this novel therapy will continue to demonstrate efficacy and safety for patients with this challenging form of cancer.

Advertisment
Chat with Dr. Medriva !